Trials / Terminated
TerminatedNCT00113256
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Astex Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and placebo) of the study. Toxicity of the drug combination will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rubitecan |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2006-02-01
- First posted
- 2005-06-07
- Last updated
- 2024-08-02
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00113256. Inclusion in this directory is not an endorsement.